Natco Pharma Ltd - 524816 - Closure of Trading Window
Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 TRADING WINDOW for dealing in the securities of the Company will be closed from 2nd February, 2019 to 14th February, 2019 (both days inclusive). Trading window will be opened from 15th February, 2019. Natco Pharma Ltd - 524816 - Board Meeting Intimation for The Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2018 And To Consider Second Interim Dividend, If Any, For The Financial Year 2018-19 And Related Matters Etc.
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2019 ,inter alia, to consider and approve The unaudited financial Results for the quarter and nine months ended 31st December, 2018 and To consider second Interim Dividend, if any, for the financial year 2018-19 and related matters etc. Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO and Alvogen file ANDA for Ibrutinib Tablets for the USA market Natco launches cardiac drug
Natco Pharma Ltd has launched Valsartan-Sacubitril tablet under its brand Valsac. The drug is a combination drug used for certain types of heart failu Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches Valsartan/Sacubitril tablet in INDIA Will agri foray turn fertile for Natco?
Natco Pharma on Friday said it is foraying into the agrichemical space and initiated work on its greenfield manufacturing facilities for producing ni NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
NATCO initiates Greenfield Facilities for Niche Agrichemical Business Natco Pharma Ltd - 524816 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- M AdinarayanaDesignation :- Company Secretary and Compliance Officer Natco Pharma Ltd - 524816 - Shareholding for the Period Ended December 31, 2018
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here Corporate Action-Intimation of Buy back
Extinguishment of 1,94,000 Equity shares of the company with respect to Buyback